| Program | Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|
|
GTx-104 |
aSAH |
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase complete
|
Phase 3 Phase in progress
|
|
GTx-102 |
Ataxia-Telangiectasia |
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
|
GTx-101 |
Postherpetic Neuralgia |
Preclinical Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
|
GTx-201 |
Undisclosed |
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
GTx-104
GTx-104 is a clinical stage, novel, injectable formulation of nimodipine being developed for intravenous infusion (IV) in aSAH patients to address significant unmet medical needs. The unique nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion.
Learn More About GTx-104GTx-102
GTX-102 is targeted as the first potential therapy for the treatment of ataxia-telangiectasia (AT) in a pediatric population. AT is caused by mutations in the ataxia telangiectasia mutated (ATM) gene. Children with AT experience cerebellar ataxia and other motor dysfunctions, oculomotor apraxia, dysarthria, and dysphagia.
A Phase-1 pharmacokinetic study was successfully completed and GTX-102 is well tolerated with no serious events reported.
GTx-101
GTx-101 is a topical administration via a bioadhesive, film-forming polymer, for treatment of pain associated with postherpetic neuralgia (PHN).
Grace Therapeutics has performed four single-dose Phase 1 studies to evaluate the PK, safety, dose proportionality and tolerability of GTx-101. No serious adverse events were reported and GTx-101 is well tolerated.
Partnerships
If you are interested in partnering with us, please contact us.
Contact Us for Partnership